Sumiyoshi Tomiki, Jayathilake Karu, Meltzer Herbert Y
Department of Psychiatry, Vanderbilt University School of Medicine, Psychiatric Hospital at Vanderbilt, 1601 23rd Avenue South, Suite 306, Nashville, TN 37212, USA.
Schizophr Res. 2003 Jul 1;62(1-2):65-72. doi: 10.1016/s0920-9964(02)00351-1.
Melperone at a dose of 300 mg/day has been reported to be as effective as thiothixene and superior to placebo in the treatment of schizophrenia. Limited ability to cause extrapyramidal side effects (EPS) and absence of an effect on plasma prolactin (pPRL) levels suggests that it is an atypical antipsychotic drug. The goal of this pilot study was to determine: (1). the ability of melperone 400 mg/day to produce greater improvement in psychopathology than melperone 100 mg/day; and (2). to compare side effects of these two doses of melperone. Melperone, 100 or 400 mg/day, was administered to 34 acutely hospitalized patients with schizophrenia for 6 weeks in a randomized, double-blind manner. Psychopathology, EPS, pPRL levels, and body mass index (BMI) were evaluated at baseline and 6 weeks. Twenty-seven completed the 6-week treatment. A last carried forward analysis revealed no significant difference in the ability of the two doses of melperone to improve psychopathology as measured by the Brief Psychiatric Rating Scale (BPRS)-Total and Positive subscale, the Scale for the Assessment of Negative Symptoms (SANS), the Schedule for Affective Disorders and Schizophrenia-Disorganization subscale, and the Global Assessment Scale (GAS). Treatment with melperone was not associated with exacerbation of EPS, or an increase in pPRL levels or BMI. The Abnormal Involuntary Movement Scale (AIMS) was not significantly changed by treatment with melperone. These results suggest that melperone was equally effective at doses 100 and 400 mg/day, for ameliorating psychopathology and improving overall psychiatric status in patients with schizophrenia. However, the lack of difference and a placebo control group, as well as modest degrees of change in psychopathology, require caution about assuming efficacy of either dose. The lack of significant side effects such as exacerbation of EPS, pPRL elevation, and weight gain indicates melperone is well tolerated.
据报道,每天服用300毫克的美哌隆在治疗精神分裂症方面与硫利达嗪效果相当,且优于安慰剂。其引起锥体外系副作用(EPS)的能力有限,对血浆催乳素(pPRL)水平无影响,表明它是一种非典型抗精神病药物。这项初步研究的目的是确定:(1)每天400毫克美哌隆在改善精神病理学方面是否比每天100毫克美哌隆更有效;(2)比较这两种剂量美哌隆的副作用。以随机、双盲的方式,对34名急性住院的精神分裂症患者给予每天100或400毫克的美哌隆,持续6周。在基线和6周时评估精神病理学、EPS、pPRL水平和体重指数(BMI)。27名患者完成了6周的治疗。末次结转分析显示,通过简明精神病评定量表(BPRS)总分和阳性分量表、阴性症状评定量表(SANS)、情感障碍和精神分裂症-紊乱分量表以及总体评定量表(GAS)衡量,两种剂量的美哌隆在改善精神病理学方面没有显著差异。美哌隆治疗与EPS加重、pPRL水平或BMI升高无关。使用美哌隆治疗后异常不自主运动量表(AIMS)没有显著变化。这些结果表明,每天100毫克和400毫克剂量的美哌隆在改善精神病理学和提高精神分裂症患者的整体精神状态方面同样有效。然而,由于缺乏差异和安慰剂对照组,以及精神病理学变化程度适中,在假设任何一种剂量的疗效时都需要谨慎。缺乏诸如EPS加重、pPRL升高和体重增加等显著副作用表明美哌隆耐受性良好。